Top

Published in:

01-04-2013 | Preclinical Study

Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?

Authors: Nigel J. Bundred, Ramachandran Prasad, Julie Morris, W. Fiona Knox, Ged Byrne, Shan Cheung, Mary Wilson, Gill Lawrence

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

Oncologists recommend chemotherapy to postmenopausal women with adverse prognostic factors, but predictors of the benefit of chemotherapy are mainly based on mortality from symptomatic cancer trials. From 1990 to 1998, 1475 breast cancers (875 screen detected cancers [SDBCs]: 600 symptomatic) were treated in women aged 50–65 years and prognostic factors compared with cancer mortality. Median follow-up was 110 months. The Nottingham Prognostic Index (NPI) was calculated for 6737 breast cancers which were part of the Association of Breast Surgery (ABS) 2001/2002 Audit of SDBCs to validate survival figures. Ten year survival was 92.1% for SDBC and 77.6% for symptomatic cancers. Adjusting for baseline factors, SDBCs had a reduced mortality (RR = 0.42 (0.31–0.57), independent of grade, node status and tumour size. Oestrogen receptor (ER) positive SDBC had a lower annual mortality rate (0.6%) compared with symptomatic (4.3%: P < 0.001) or ER negative SDBC (1.8%). Epithelial proliferation was lower in SDBC in all NPI groups compared with symptomatic cancers (P ≤ 0.001). Grade, node status, ER status, size and mode of detection predicted survival. Survival for each NPI group was better for SDBC. For ER positive SDBC in the Moderate Prognostic Group 1 (MPG1), 10 year mortality was 6.4% compared with 17.6% in symptomatic (P = 0.001). NPI on 6,737 operable SDBC confirmed similar mortality in all groups (4% mortality in MPG1 group). SDBC have lower mortality than symptomatic due to a lower proliferative index. The use of adjuvant chemotherapy is over-treatment for ER positive SDBCs with Good Prognostic Group (GPG) and MPG1 NPI scores.

Available only for authorised users

Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE (2002) Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359(9310):909–919 Review. Erratum in: Lancet 2002 Aug 31;360(9334):724PubMedCrossRef

Duffy SW, Tabár L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, Epstein B, Frodis E, Ljungberg E, Hedborg-Melander C, Sundbom A, Tholin M, Wiege M, Akerlund A, Wu HM, Tung TS, Chiu YH, Chiu CP, Huang CC, Smith RA, Rosén M, Stenbeck M, Holmberg L (2002) The impact of organised mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 95(3):458–469PubMedCrossRef

Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC (1999) The Natural History of Breast Carcinoma. What have we learned from screening? Cancer 86:449–462PubMedCrossRef

Blamey RW, Wilson ARM, Patnick J (2000) ABC of breast diseases—screening for breast cancer. BMJ 321:689–693PubMedCrossRef

Crisp WJ, Higgs MJ, Cowan WK, Cunliffe WJ, Liston J, Lunt LG, Peakman DJ, Young JR (1993) Screening for breast cancer detects tumours at an earlier biological stage. Br J Surg 80(7):863–865PubMedCrossRef

Joensuu H, Lehtimaki T, Holli K, Elomae L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J (2004) Risk for distant recurrence of breast cancer detected by mammographic screening or other methods. JAMA 292:1064–1073PubMedCrossRef

Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC (2009) Molecular characteristics of screen-detected vs. symptomatic breast cancers and their impact on survival. Br J Cancer 101(8):1338–1344PubMedCrossRef

Lawrence G, Wallis M, Allgood P, Nagtegaal ID, Warwick J, Cafferty FH, Houssami N, Kearins O, Tappenden N, O’Sullivan E, Duffy SW (2009) Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 116(1):179–185 Epub 2008 Jul 12PubMedCrossRef

Møller H, Sandin F, Bray F, Klint A, Linklater KM, Purushotham A, Robinson D, Holmberg L (2010) Breast cancer survival in England, Norway and Sweden: a population-based comparison. Int J Cancer 127(11):2630–2638PubMedCrossRef

10.

Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef

11.

Ravdin PM (1995) A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients. Bull Cancer 82 Suppl 5:561s-564s. http://www.adjuvantonline.com

12.

Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK (2009) Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9707):2055–2063PubMedCrossRef

13.

Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16(8):2651–2658PubMed

14.

Scottish Cancer Therapy Network SIGN Guidelines for breast cancer women Section 10 Adjuvant Systemic Therapy. Scottish Intercollegiate Guidelines Network 1998 Breast Cancer. SIGN, Edinburgh

15.

Blamey R (1996) The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast 5:154–167CrossRef

16.

Feldman M, Stanford R, Catcheside A, Stotter A (2002) The use of a prognostic table to aid decision making on adjuvant therapy for women with early breast cancer. EJSO 28:615–619PubMedCrossRef

17.

An audit of SDBCs for the year of screening April 2001 to March 2002. Association of Breast surgery at BASO (British Association of Surgical Oncology) 2nd April 2003. NHS Cancer Screening Programmes 2003 (www.cancerscreening.nhs.uk)

18.

Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M (2004) The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40(3):342–351PubMedCrossRef

19.

Elston CW, Ellis IO (1991) The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (Oxf) 19:403–410CrossRef

20.

Holland PA, Walls J, Boggis CR, Knox F, Baildam AD, Bundred NJ (1996) A comparison of axillary node status between cancers detected at the prevalence and first incidence breast screening rounds. Br J Cancer 74(10):1643–1646PubMedCrossRef

21.

Boland G, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal cancer in situ. Br J Cancer 90:423–429PubMedCrossRef

22.

Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, the ICBP Module 1 Working Group (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377:127–138PubMedCrossRef

23.

Mook S, Van’t Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, Visser O, Schmidt MK (2011) Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103:585–597PubMedCrossRef

24.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) ATAC trialists’ group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRef

25.

Kalager M, Zelen M, Langmark F, Adami H (2010) Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 363:1203–1210PubMedCrossRef

Title: Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?
Authors: Nigel J. Bundred
Ramachandran Prasad
Julie Morris
W. Fiona Knox
Ged Byrne
Shan Cheung
Mary Wilson
Gill Lawrence
Publication date: 01-04-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1652-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response

Earwax type and osmidrosis: prognostic factor for breast cancer?

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up

Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort

The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse

Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer